Retrospective Study
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Sep 16, 2023; 11(26): 6066-6072
Published online Sep 16, 2023. doi: 10.12998/wjcc.v11.i26.6066
Lyophilized recombinant human brain natriuretic peptide for chronic heart failure: Effects on cardiac function and inflammation
Feng Li, Hao Li, Rong Luo, Jia-Bao Pei, Xue-Ying Yu
Feng Li, Hao Li, Rong Luo, Jia-Bao Pei, Xue-Ying Yu, Department of Cardiovascular Internal Medicine, People's Hospital of Jieshou, Jieshou 236500, Anhui Province, China
Author contributions: Li F and Li H contributed equally to this work; Li F, Li H, Luo R, Pei JB, and Yu XY designed the research study; Li F, Li H, Pei JB, and Luo R performed the research; Yu XY and Li F contributed new reagents and analytic tools; Li F, Li H and Pei JB analyzed the data and wrote the manuscript; and all authors have read and approve the final manuscript.
Institutional review board statement: The study was reviewed and approved by the People's Hospital of Jieshou Institutional Review Board.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: All authors have no conflicts of interest.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Feng Li, Associate Chief Physician, Master's Student, Department of Cardiovascular Internal Medicine, People's Hospital of Jieshou, No. 399 Renmin East Road, Jieshou 236500, Anhui Province, China. lff753159789@163.com
Received: April 24, 2023
Peer-review started: April 24, 2023
First decision: May 8, 2023
Revised: May 20, 2023
Accepted: August 3, 2023
Article in press: August 3, 2023
Published online: September 16, 2023
Processing time: 137 Days and 1.5 Hours
ARTICLE HIGHLIGHTS
Research background

Chronic heart failure (CHF) needs effective treatment, and the lyophilized recombinant human brain natriuretic peptide (BNP) has the potential to improve heart function and inhibit myocardial remodeling.

Research motivation

This study explored the potential of lyophilized recombinant human BNP therapy as a safe and effective treatment for CHF patients and to determine its ability to improve the clinical outcomes and overall quality of life in these patients.

Research objectives

This study aimed to investigate the effects of freeze-dried recombinant human BNP therapy on cardiac function and microinflammatory status in CHF patients and compare the clinical efficacy, inflammatory factor levels, myocardial damage, cardiac function, and adverse reactions with those of standard HF therapy.

Research methods

A total of 102 CHF patients were randomly assigned to the control or observation group, and both groups received treatment for 3 d. The control group received standard HF therapy, and the observation group received recombinant human BNP therapy. Clinical efficacy, inflammatory factor levels, myocardial damage, cardiac function, and adverse reactions were compared between the two groups before and after treatment.

Research results

After treatment, the observation group exhibited higher overall clinical efficacy than the control group. Serum high sensitivity C-reactive protein, N-terminal proBNP, and troponin I levels were lower in both groups after than before treatment, with greater reductions noted in the observation group. Physical, emotional, social, and economic scores were also lower in both groups after than before treatment, with greater improvements noted in the observation group. No significant difference was observed in the incidence of adverse reactions between the two groups. These findings suggest that freeze-dried recombinant human BNP therapy is safe and reliable and can improve heart function and reduce microinflammation in CHF patients.

Research conclusions

Freeze-dried recombinant human BNP therapy effectively improves heart function, reduces microinflammation, and enhances the overall quality of life of CHF patients. It causes no significant adverse reactions. These results suggest that this therapy can potentially be used as a safe and reliable treatment for CHF, and further studies are warranted to explore its long-term efficacy and safety.

Research perspectives

Future studies can focus on exploring the long-term efficacy and safety of freeze-dried recombinant human BNP therapy in CHF patients, as well as on investigating its potential use in combination with other therapies for improving clinical outcomes. Additional studies may be warranted to explore the underlying mechanisms to clarify how this therapy improves heart function and reduces microinflammation.